Evidence map›Paper›PMID 25942398›Full record

Trial reportBritish journal of cancer2015

(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.

J J You, K J Cline, C-S Gu, K I Pritchard, I S Dayes, K Y Gulenchyn, R I Inculet, S K Dhesy-Thind, M A Freeman, A M Chan and 2 more

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. EANM guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2021
    Guideline
  2. Prospective study onBritish journal of cancer · 2026
    Trial
  3. Article
  4. Article
  5. Examining the evolving utility ofTranslational cancer research · 2020
    Review
  6. Article
  7. Intended Versus Inferred Treatment AfterJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

J J You1] Department of Medicine, McMaster University, 1280 Main Street West, Room HSC-2C8, Hamilton, Ontario L8S 4K1, Canada [2] Department of Clinical Epidemiology & Biostatistics, McMaster University, 1280 Main Street West, Room HSC-2C8, Hamilton, Ontario L8S 4K1, Canada.
K J ClineOntario Clinical Oncology Group, Department of Oncology, McMaster University, 711 Concession Street, G Wing, Hamilton, Ontario L8V 1C3, Canada.
C-S GuOntario Clinical Oncology Group, Department of Oncology, McMaster University, 711 Concession Street, G Wing, Hamilton, Ontario L8V 1C3, Canada.
K I PritchardSunnybrook Odette Cancer Centre, Department of Medicine, University of Toronto, T2-107, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
I S DayesDepartment of Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, Ontario L8V 5C3, Canada.
K Y GulenchynDepartment of Nuclear Medicine & Molecular Imaging, Hamilton Health Sciences & St Joseph's Healthcare Hamilton, McMaster University, 1200 Main Street West, Room HSC-1P15, Hamilton, Ontario L8N 3Z5, Canada.
R I InculetDepartment of Surgery, Division of Thoracic Surgery, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, Suite E2-122, London, Ontario N6A 5W9, Canada.
S K Dhesy-ThindDepartment of Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, Ontario L8V 5C3, Canada.
M A FreemanDepartment of Medical Imaging, University of Toronto, University Health Network, Eaton Wing, 1-ES-416, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.
A M ChanDepartment of Oncology, Thunder Bay Regional Health Sciences Centre, 980 Oliver Road, Thunder Bay, Ontario P7B 6V4, Canada.
J A JulianOntario Clinical Oncology Group, Department of Oncology, McMaster University, 711 Concession Street, G Wing, Hamilton, Ontario L8V 1C3, Canada.
M N Levine1] Ontario Clinical Oncology Group, Department of Oncology, McMaster University, 711 Concession Street, G Wing, Hamilton, Ontario L8V 1C3, Canada [2] Department of Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, 699 Concession Street, Hamilton, Ontario L8V 5C3, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSometimes the diagnosis of recurrent cancer in patients with a previous malignancy can be challenging. This prospective cohort study assessed the clinical utility of (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography ((18)F-FDG PET-CT) in the diagnosis of clinically suspected recurrence of cancer.

methodsPatients were eligible if cancer recurrence (non-small-cell lung (NSCL), breast, head and neck, ovarian, oesophageal, Hodgkin's or non-Hodgkin's lymphoma) was suspected clinically, and if conventional imaging was non-diagnostic. Clinicians were asked to indicate their management plan before and after (18)F-FDG PET-CT scanning. The primary outcome was change in planned management after (18)F-FDG PET-CT.

resultsBetween April 2009 and June 2011, 101 patients (age, median 65 years; 55% female) were enroled from four cancer centres in Ontario, Canada. Distribution by primary tumour type was: NSCL (55%), breast (19%), ovarian (10%), oesophageal (6%), lymphoma (6%), and head and neck (4%). Of the 99 subjects who underwent (18)F-FDG PET-CT, planned management changed after (18)F-FDG PET-CT in 52 subjects (53%, 95% confidence interval (CI), 42-63%); a major change in plan from no treatment to treatment was observed in 38 subjects (38%, 95% CI, 29-49%), and was typically associated with (18)F-FDG PET-CT findings that were positive for recurrent cancer (37 subjects). After 3 months, the stated post-(18)F-FDG PET-CT management plan was actually completed in 88 subjects (89%, 95% CI, 81-94%).

conclusionIn patients with suspected cancer recurrence and conventional imaging that is non-diagnostic, (18)F-FDG PET-CT often provides new information that leads to important changes in patient management.

Indexed as

Fluorodeoxyglucose F18AdultAgedAged, 80 and overCanadaFemaleHumansMaleMiddle AgedMultimodal ImagingNeoplasm Recurrence, LocalNeoplasmsPositron-Emission TomographyRadiographyFluorodeoxyglucose F18

Identifiers

PMID25942398
PMCPMC4647251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.